Literature DB >> 7678073

The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms.

C E Van Rensburg1, A M Van Staden, R Anderson.   

Abstract

Clofazimine, a riminophenazine antimicrobial agent, and its analogue B669 were investigated for their effects on FaDu cells, a human squamous carcinoma cell line. These agents, at concentrations within the therapeutic range (0.25-2 micrograms/ml), caused a dose-dependent tumor cell cytotoxicosis which was greatly enhanced in the presence of human neutrophils. The neutrophil-mediated increment in tumoricidal activity, but not the direct antitumor effects of the drugs per se, was inhibited by catalase. The effects of these drugs on three more cell carcinoma lines as well as on two primary cultures and a noncarcinoma cell line were also investigated and compared with the activity of the standard antitumor chemotherapeutic agents bleomycin, cisplatin, and methotrexate. All seven cultures were sensitive to clofazimine and B669 compared to six that were sensitive to cisplatin, three that were sensitive to bleomycin, and one that was sensitive to methotrexate. The treatment of FaDu cells with clofazimine and B669 was associated with enhanced activity of phospholipase A2, as evidenced by increased release of radiolabeled arachidonate and lysophosphatidylcholine from membrane phospholipids. Inhibitors of arachidonic acid metabolism, protein kinase C inhibitors, as well as water and lipid soluble antioxidants failed to protect the cells against the cytotoxic activity of clofazimine and B669. However, alpha-tocopherol, a lysophospholipid-complexing agent, completely blocked the antiproliferative effects of the riminophenazines and also protected the cells against the direct cytotoxic effect of lysophosphatidylcholine, while the lysophospholipid-neutralizing enzyme lysophospholipase protected against the riminophenazines. These observations demonstrate that the tumoricidal properties of clofazimine and B669 are probably due to increases in the lysophospholipid content of cell membranes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678073

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma.

Authors:  Anna Bianchi-Smiraglia; Archis Bagati; Emily E Fink; Hayley C Affronti; Brittany C Lipchick; Sudha Moparthy; Mark D Long; Spencer R Rosario; Shivana M Lightman; Kalyana Moparthy; David W Wolff; Dong Hyun Yun; Zhannan Han; Anthony Polechetti; Matthew V Roll; Ilya I Gitlin; Katerina I Leonova; Aryn M Rowsam; Eugene S Kandel; Andrei V Gudkov; P Leif Bergsagel; Kelvin P Lee; Dominic J Smiraglia; Mikhail A Nikiforov
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

2.  HLA expression in hepatocellular carcinoma cell lines.

Authors:  A A Wadee; A Paterson; K A Coplan; S G Reddy
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

3.  Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.

Authors:  Takahiro Yano; Sacha Kassovska-Bratinova; J Shin Teh; Jeffrey Winkler; Kevin Sullivan; Andre Isaacs; Norman M Schechter; Harvey Rubin
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

4.  Tetramethylpiperidine-substituted phenazines inhibit the proliferation of intrinsically multidrug resistant carcinoma cell lines.

Authors:  E van Niekerk; J F O'Sullivan; G K Jooné; C E van Rensburg
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

5.  Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation.

Authors:  Dwayne Koot; Duncan Cromarty
Journal:  Drug Deliv Transl Res       Date:  2015-06       Impact factor: 4.617

6.  Increased generation of intracellular reactive oxygen species initiates selective cytotoxicity against the MCF-7 cell line resultant from redox active combination therapy using copper-thiosemicarbazone complexes.

Authors:  Fady N Akladios; Scott D Andrew; Christopher J Parkinson
Journal:  J Biol Inorg Chem       Date:  2016-03-07       Impact factor: 3.358

7.  Clofazimine Inhibits the Growth of Babesia and Theileria Parasites In Vitro and In Vivo.

Authors:  Bumduuren Tuvshintulga; Mahmoud AbouLaila; Batdorj Davaasuren; Aki Ishiyama; Thillaiampalam Sivakumar; Naoaki Yokoyama; Masato Iwatsuki; Kazuhiko Otoguro; Satoshi Ōmura; Ikuo Igarashi
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

8.  Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response.

Authors:  Jason Baik; Kathleen A Stringer; Gerta Mane; Gus R Rosania
Journal:  Antimicrob Agents Chemother       Date:  2012-12-21       Impact factor: 5.191

9.  Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells.

Authors:  Luigi Leanza; Brian Henry; Nicola Sassi; Mario Zoratti; K George Chandy; Erich Gulbins; Ildikò Szabò
Journal:  EMBO Mol Med       Date:  2012-04-11       Impact factor: 12.137

10.  Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization.

Authors:  Jason Baik; Gus R Rosania
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.